Menu
Back to User profile » Dr Francesco Menzella
Papers published by Dr Francesco Menzella:
Clinical Features and Efficacy of Benralizumab in Patients with Blood Eosinophil Count Between 300 and 450 Cells/mm3: A Post Hoc Analysis from the ANANKE Study
Senna G, Aliani M, Altieri E, Bracciale P, Brussino L, Caiaffa MF, Cameli P, Canonica GW, Caruso C, D'Amato M, De Michele F, Del Giacco S, Di Marco F, Menzella F, Pelaia G, Rogliani P, Romagnoli M, Schino P, Schroeder JW, Vultaggio A, Rizzoli S, Zullo A, Boarino S, Palmisano M, Rossi A, Vitiello G, Centanni S
Journal of Asthma and Allergy 2022, 15:1593-1604
Published Date: 10 November 2022
Efficacy and Safety of Omalizumab Treatment Over a 16-Year Follow-Up: When a Clinical Trial Meets Real-Life
Menzella F, Fontana M, Contoli M, Ruggiero P, Galeone C, Capobelli S, Simonazzi A, Catellani C, Scelfo C, Castagnetti C, Livrieri F, Facciolongo N
Journal of Asthma and Allergy 2022, 15:505-515
Published Date: 21 April 2022
A Real-World Evaluation of Clinical Outcomes of Biologicals and Bronchial Thermoplasty for Severe Refractory Asthma (BIOTERM)
Menzella F, Fontana M, Galeone C, D'Amato M, Canonica GW, Ghidoni G, Capobelli S, Scelfo C, Simonazzi A, Catellani C, Ruggiero P, Facciolongo N
Journal of Asthma and Allergy 2021, 14:1019-1031
Published Date: 13 August 2021
Profile of Anti-IL-5 mAb Mepolizumab in the Treatment of Severe Refractory Asthma and Hypereosinophilic Diseases [Corrigendum]
Menzella F, Lusuardi M, Galeone C, Taddei S, Zucchi L
Journal of Asthma and Allergy 2021, 14:753-754
Published Date: 29 June 2021
Real-World Experience with Benralizumab in Patients with Severe Eosinophilic Asthma: A Case Series
Menzella F, Bonavia M, Bonini M, D'Amato M, Lombardo S, Murgia N, Patella V, Triggiani M, Pelaia G
Journal of Asthma and Allergy 2021, 14:149-161
Published Date: 22 February 2021
May 2020: Is It Always COVID-19 No Matter What?
Livrieri F, Ghidoni G, Piro R, Menzella F, Cavazza A, Lazzaretti C, Massari M, Montanari G, Fontana M, Facciolongo NC
International Medical Case Reports Journal 2020, 13:563-567
Published Date: 2 November 2020
A Dangerous Consequence of the Recent Pandemic: Early Lung Fibrosis Following COVID-19 Pneumonia – Case Reports
Scelfo C, Fontana M, Casalini E, Menzella F, Piro R, Zerbini A, Spaggiari L, Ghidorsi L, Ghidoni G, Facciolongo NC
Therapeutics and Clinical Risk Management 2020, 16:1039-1046
Published Date: 29 October 2020
Anti-IL5 Therapies for Severe Eosinophilic Asthma: Literature Review and Practical Insights
Menzella F, Ruggiero P, Ghidoni G, Fontana M, Bagnasco D, Livrieri F, Scelfo C, Facciolongo N
Journal of Asthma and Allergy 2020, 13:301-313
Published Date: 9 September 2020
A case of chronic eosinophilic pneumonia in a patient treated with dupilumab
Menzella F, Montanari G, Patricelli G, Cavazza A, Galeone C, Ruggiero P, Bagnasco D, Facciolongo N
Therapeutics and Clinical Risk Management 2019, 15:869-875
Published Date: 10 July 2019
Near-fatal asthma responsive to mepolizumab after failure of omalizumab and bronchial thermoplasty
Menzella F, Galeone C, Lusuardi M, Simonazzi A, Castagnetti C, Ruggiero P, Facciolongo N
Therapeutics and Clinical Risk Management 2017, 13:1489-1493
Published Date: 8 November 2017
Bronchial thermoplasty and the role of airway smooth muscle: are we on the right direction?
Menzella F, Lusuardi M, Galeone C, Facciolongo N
Therapeutics and Clinical Risk Management 2017, 13:1213-1221
Published Date: 19 September 2017
Innovative treatments for severe refractory asthma: how to choose the right option for the right patient?
Menzella F, Galeone C, Bertolini F, Castagnetti C, Facciolongo N
Journal of Asthma and Allergy 2017, 10:237-247
Published Date: 30 August 2017
Clinical usefulness of mepolizumab in severe eosinophilic asthma
Menzella F, Lusuardi M, Montanari G, Galeone C, Facciolongo N, Zucchi L
Therapeutics and Clinical Risk Management 2016, 12:907-916
Published Date: 8 June 2016
Profile of anti-IL-5 mAb mepolizumab in the treatment of severe refractory asthma and hypereosinophilic diseases
Menzella F, Lusuardi M, Galeone C, Taddei S, Zucchi L
Journal of Asthma and Allergy 2015, 8:105-114
Published Date: 8 October 2015